Compare iShares MSCI China ETF (MCHI) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Nuwellis Inc — how do they compare? iShares MSCI China ETF trades at $51.85 (market cap $6.00B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: iShares MSCI China ETF is far larger — about 2727.3× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 1,917,899). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Nuwellis Inc for 26 Days on average.
| MCHI | NUWE | |
|---|---|---|
Market Cap | $6.00B | $2.20M |
Volume | 1,917,899 | 121,544 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $146.65 |
52-Week Low | $50.48 | $0.68 |
Typical Hold Time | 63 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $51.64, down 1.11% with a bearish technical signal from moving averages and oscillators. The ETF faces headwinds from China's economic challenges including industrial overcapacity and trade tensions, though corporate profits surged 26% in Q2 2026. Support levels cluster around $51-52 with resistance at $52, indicating consolidation near current levels amid mixed market sentiment.
The outlook remains cautious due to China's macroeconomic pressures and global trade friction, though historical discount to US indices presents potential value. Key risks include export restrictions, protectionism threats, and domestic consumption weakness. Institutional activity shows mixed positioning with recent acquisitions offset by reductions.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
